Ellevest Inc. Sells 3,964 Shares of Sanofi $SNY

Ellevest Inc. reduced its holdings in Sanofi (NASDAQ:SNY) by 20.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,381 shares of the company’s stock after selling 3,964 shares during the quarter. Ellevest Inc.’s holdings in Sanofi were worth $743,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Capital Analysts LLC grew its position in shares of Sanofi by 14.0% in the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after buying an additional 204 shares during the last quarter. Thomasville National Bank grew its position in shares of Sanofi by 0.3% in the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after buying an additional 211 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its stake in shares of Sanofi by 4.1% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after purchasing an additional 247 shares during the period. Whipplewood Advisors LLC lifted its stake in shares of Sanofi by 18.2% in the 2nd quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Sanofi by 6.7% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,032 shares of the company’s stock valued at $224,000 after purchasing an additional 253 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SNY shares. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Stock Down 0.2%

Shares of NASDAQ:SNY opened at $49.00 on Thursday. The stock has a fifty day simple moving average of $48.64 and a two-hundred day simple moving average of $49.51. The stock has a market capitalization of $120.32 billion, a price-to-earnings ratio of 11.48, a PEG ratio of 1.38 and a beta of 0.51. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.25 earnings per share. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.